Shahar Shelly | Epidemiology | Best Researcher Award

Posted on by Neuroscientists

Dr. Shahar Shelly | Epidemiology | Best Researcher Award

Dr. Shahar Shelly,  Rambam Medical Center, Israel.

Dr. Shahar Shelly, MD, is a globally recognized neurologist and researcher specializing in neuroimmunology and neuromuscular disorders. With academic roles across Rambam Medical Center, Technion Institute, and the Mayo Clinic, Dr. Shelly has driven advancements in clinical diagnostics, treatment strategies, and disease understanding.

 

profile

Scholor

🎓 Education

University Medical School of Hungary, Debrecen – Summa Cum Laude (01/2005–01/2012). Shamir Medical Center, Zerifin, Israel – Internship (Cum Laude) (01/2012–01/2013). Sheba Medical Center – Residency, Neurology Department (01/2013–01/2017). Mayo Clinic, Rochester, MN – Neuroimmunology Fellowship (04/2018–07/2019). Neuromuscular Disorders, Muscle Fellowship – Mayo Clinic (07/2019–07/2020) Neuromuscular Disorders, Nerve Fellowship – Mayo Clinic (07/2020–07/2021).

📜 Certifications

Israeli Neurology Board Certification (2018). Educational Commission for Foreign Medical Graduates (ECFMG) (2018). Mayo Clinic Quality Fellow Certification (2019). Medical Genetics Certificate – Recanti Genetic Institute (2015). Advanced Electrophysiology Certification – Board-Licensed Electromyography (2019).

🏆 Honors & Awards

Summa Cum Laude – University Medical School of Hungary.  Cum Laude – Hassaf Harofeh Medical Center Internship.Israel Medical Association Fellowship Award (2017). Best Abstract Award – American Academy of Neurology (2019).

🔬 Patents & Innovations

Digital Drug Amplifier – Combines digital therapeutics with pharmaceuticals (FDA-approved). IMNM Muscle Disease Screening Software – Released for public use in the USA (2020).

🌐 Professional Memberships

American Neurological Association.Israeli Neuromuscular Society.American Association of Neuromuscular & Electrodiagnostic Medicine

📚 Publications

  • Prolactin and autoimmunity
    Authors: S Shelly, M Boaz, H Orbach
    Year: 2012

 

  • Autonomic dysfunction following COVID-19 infection: an early experience
    Authors: K Shouman, G Vanichkachorn, WP Cheshire, MD Suarez, S Shelly, et al.
    Year: 2021

 

  • Thymoma and autoimmunity
    Authors: S Shelly, N Agmon-Levin, A Altman, Y Shoenfeld
    Year: 2011

 

  • Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy
    Authors: S Shelly, JD Triplett, MV Pinto, M Milone, FE Diehn, A Zekeridou, et al.
    Year: 2020

 

  • Epidemiology and natural history of inclusion body myositis: a 40-year population-based study
    Authors: S Shelly, MM Mielke, J Mandrekar, M Milone, FC Ernste, E Naddaf, et al.
    Year: 2021

 

  • Survival and associated comorbidities in inclusion body myositis
    Authors: E Naddaf, S Shelly, J Mandrekar, AM Chamberlain, EM Hoffman, et al.
    Year: 2022

 

  • Small fiber neuropathy incidence, prevalence, longitudinal impairments, and disability
    Authors: SA Johnson, K Shouman, S Shelly, P Sandroni, SE Berini, PJB Dyck, et al.
    Year: 2021

 

  • Neurochondrin neurological autoimmunity
    Authors: S Shelly, TJ Kryzer, L Komorowski, R Miske, MD Anderson, EP Flanagan, et al.
    Year: 2019

 

  • Potential neurotoxicity of titanium implants: Prospective, in-vivo and in-vitro study
    Authors: S Shelly, SL Zaltsman, O Ben-Gal, A Dayan, I Ganmore, C Shemesh, et al.
    Year: 2021

 

  • Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes
    Authors: S Shelly, CJ Klein, PJB Dyck, P Paul, ML Mauermann, SE Berini, B Howe, et al.
    Year: 2021

 

Conclusion

Dr. Shahar Shelly exemplifies excellence in clinical practice, academic leadership, and innovative research. His focus on using cutting-edge technologies like AI and biomarker discovery aims to transform the diagnosis and treatment of complex neurological and neuromuscular disorders. Driven by a commitment to precision medicine, his career reflects a blend of academic rigor, clinical expertise, and groundbreaking contributions that continue to shape the future of neurology.

 

 

Baoying Huang | Pathogen Biology | Best Researcher Award

Posted on by Neuroscientists

Baoying Huang | Pathogen Biology | Best Researcher Award

Ms. Baoying Huang,  National Institute for Viral Disease Control and Prevention, China.

Dr. Baoying Huang, a distinguished professor at the Biotech Center for Viral Disease Emergency, China CDC, has over two decades of experience in combating viral diseases. Her expertise lies in vaccine and antiviral drug development for emerging and re-emerging infectious diseases, including COVID-19, monkeypox, and other human coronaviruses.

 

profile

Scopus

🎓 Education Experience

2008.09–2011.07: Doctor of Medicine, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC.2005.09–2008.07: Master of Biology, Pathogen Biology,Biotech Center for Viral Disease Emergency, China CDC. 2001.09–2005.07: Bachelor of Biology,
Life Science Department, Nan Hua University, China.

👩‍🔬 Professional Experience

2020.07–Present:  Professor, China CD ,Focus: Vaccine and antiviral drug R&D for SARS-CoV-2 and poxvirus diseases, including COVID-19 and monkeypox. Key Role: Participated in COVID-19 Emergency Projects for SARS-CoV-2 variant monitoring in China.2015.07–2020.07:  Associate Professor, China CDC. Focus: Vaccine and antiviral drug R&D for emerging infectious diseases like influenza and coronaviruses (SARS-CoV, MERS-CoV).2015.04–2015.06:  Assistant Professor, China CDC. Global Health Support Program: Worked in Sierra Leone to establish Ebola lab systems, improving public health infrastructure.2011.07–2015.07: Assistant Professor, China CDC. Focus: Pathogenic molecular mechanisms of influenza viruses, pseudo-virus applications, and gene-engineered vaccines. 2005.09–2011.07:  Graduate Researcher, IVDC, China CDC. Specialization: Developing universal influenza vaccines for cross-protection against various strains.

🔬 Research Focus

Baoying Huang’s work is dedicated to:Vaccine Development: COVID-19 vaccines (BBIBP-CorV, mRNA vaccines) and pan-orthopoxvirus solutions.Emerging Diseases: Countermeasures for SARS-CoV-2, monkeypox, and other viral threats.Diagnostics: Whole-genome sequencing and real-time PCR for virus detection and monitoring.Therapeutics: Screening novel antivirals targeting viruses like SARS-CoV-2 and monkeypox.Key achievements include:Leading the development of Sinopharm COVID-19 vaccine, later approved by WHO for Emergency Use Listing.Establishing monitoring systems for SARS-CoV-2 variants and assessing their impact on public health measures. Advancing monkeypox vaccine research and identifying promising antiviral compounds against orthopoxviruses.

📚 Publications

  • Title: Molecular architecture of monkeypox mature virus
    • Authors: Hong, Y., Huang, B., Zhang, J., Tan, W., Li, S.
    • Year: 2024

 

  • Title: Vaccinia virus Tiantan strain blocks host antiviral innate immunity and programmed cell death by disrupting gene expression
    • Authors: Wu, C., Zhang, Z., Li, Z., Deng, Y., Tan, W.
    • Year: 2024

 

  • Title: A clinically used anti-human papilloma virus agent (3-hydroxyphthalic anhydride-modified bovine β-lactoglobulin) has a potential for topical application to prevent sexual transmission of monkeypox virus
    • Authors: Sha, Y., Huang, B., Hua, C., Tan, W., Jiang, S.
    • Year: 2024

 

  • Title: Development of a multiplex real-time PCR assay for the simultaneous detection of mpox virus and orthopoxvirus infections
    • Authors: Fan, Z., Xie, Y., Huang, B., Tan, W., Guo, F.
    • Year: 2024

 

  • Title: Accurate determination of the whole genome sequencing and open reading frames composition of non-replicating Tiantan strain of vaccinia virus based on novel long read sequencing platform
    • Authors: Zhang, Z., Wu, C., Li, H., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Characterization of whole genomes from recently emerging Mpox cases in several regions of China, 2023
    • Authors: Wu, C., Cui, L., Pan, Y., Wang, Q., Tan, W.
    • Year: 2024

 

  • Title: Intranasal immunization with single-dose vaccine based on recombinant influenza virus H1N1 expressing the extracellular domain of respiratory syncytial virus G protein induces robust immunity and protection in mice
    • Authors: Han, R., Wang, D., Wang, T., Huang, B., Tan, W.
    • Year: 2024

 

  • Title: Rapid identification of full-length genome and tracing variations of monkeypox virus in clinical specimens based on mNGS and amplicon sequencing
    • Authors: Wu, C., A, R., Ye, S., Lu, J., Tan, W.
    • Year: 2024

 

  • Title: Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population
    • Authors: Li, M., Guo, Y., Deng, Y., Gao, G.F., Liu, J.
    • Year: 2024

 

  • Title: Identification of the VP37 pocket of monkeypox virus as a promising target for pan-orthopoxvirus inhibitors through virtual screening and antiviral assays
    • Authors: Huo, S., Wu, L., Huang, B., Xu, Z., Tan, W.
    • Year: 2024

 

Conclusion

Dr. Huang’s career exemplifies unwavering dedication to improving public health through innovation in vaccine development, antiviral research, and diagnostic technologies. Her contributions to tackling global health challenges, such as the COVID-19 pandemic and monkeypox outbreaks, have significantly impacted infectious disease prevention and control worldwide. As viruses continue to evolve, her pioneering work remains a cornerstone in safeguarding global health.